Geron Cellvane, a company specializing in the production of prescription pharmaceuticals, announced on June 30 that it successfully concluded its exhibition and lecture at the "ASLS TOKYO 2025," the Japanese academic conference of the Korean Association of Aesthetic Plastic Laser Medicine, held in Tokyo, Japan.
At this academic conference, Geron Cellvane delivered a successful lecture on the topic of "Clinical Cases of PDRN Skin Boosters and PN Fillers." Through its exhibition booth, the company officially introduced its PDRN-based "Cellvane Skin Booster," the export PN healer "Kledence," and the prescription pharmaceutical "Cellvane Inj." to medical professionals from both Korea and Japan, attracting significant attention.
Geron Cellvane applies its proprietary patented technology, Prism Technology (Prism-T), which enables smaller and more uniform molecular size, thereby achieving both high absorption rates and safety. The company has demonstrated outstanding results in clinical settings.
In particular, "Cellvane Inj." is an effective prescription pharmaceutical for promoting tissue regeneration and is actively used in dermatology and pain treatment fields.
"ASLS TOKYO 2025" is the first academic conference held in Japan by the Korean Association of Aesthetic Plastic Laser Medicine, featuring lectures introducing the latest trends and technologies in aesthetic medicine as well as exhibitions of advanced medical products. With the participation of a large number of medical professionals from both Korea and Japan, Geron Cellvane enhanced its technological reputation and brand credibility.
According to the company, approximately 500 medical professionals attended the lecture, demonstrating high interest and positive response from those in the medical field.
Kim Deokgyu, CEO of Geron Cellvane, stated, "Participating in this Japanese academic conference provided an opportunity to raise awareness of our products in the local market and to strengthen our global competitiveness. We will continue to pursue various opportunities for academic exchange to enhance our corporate value."
He added, "We plan to continuously introduce high value-added aesthetic solutions based on regenerative medicine technology, and will actively expand the overseas presence of our PDRN and PN-based products through our global distribution network."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
